UNSPSC 51171922: Tegaserod

This classification denotes a serotonin antagonist with the molecular formula C16H23N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 458VC51857, chemically known as hydrazinecarboximidamide, 2-((5-methoxy-1h-indol-3-yl)methylene)-n-pentyl- but generally known as tegaserod, which bears US NIH Compound Identifier 5487301. European Medicines Agency schedules Tegaserod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04713MIG.

UNSPSC 51171922 Tegaserod, a Commodity code, represents pharmaceutical products procured by state and local health agencies and correctional departments for clinical and institutional use. Recent state and local solicitations under this code reflect demand for generic pharmaceuticals, over-the-counter products, and specialized pharmaceutical services distributed through established wholesaler networks and direct-to-manufacturer models. State and local buyers—including county corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances—are pursuing contracts that emphasize cost management, supply chain security, and compliance with FDA and Drug Supply Chain Security Act requirements. The scope of work encompasses manufacturer pricing for identified pharmaceutical products with specific National Drug Codes, specimen collection and drug testing services in correctional settings, and exploratory procurement for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, solicited generic multi-source pharmaceuticals and OTC products on January 20, 2026 with a March 26, 2026 response deadline under RFP S1070000015802, distributing across state and local government facilities including Oregon. Collin County Community Supervision and Corrections Department in Texas issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a July 23, 2026 deadline, seeking lab-certified vendors to conduct approximately 25,031 annual tests across two collection sites at an estimated contract value of $600,000 over two years with three optional one-year renewal periods. The Texas Health and Human Services Commission issued RFI No. HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription capabilities, signaling future formal procurement. Recent activity concentrates in Texas and the Upper Midwest (Minnesota and participating jurisdictions), with multistate cooperative purchasing vehicles and state health agencies driving consolidated demand across correctional, pharmacy benefit, and general institutional procurement.